Connect with us

Life Sciences

Durham-based Codetta Bio names new CEO

Codetta Bio, a developer of biomarker measurement tools, has named a new chief executive officer.
The post Durham-based Codetta Bio names new CEO first…

Published

on

This article was originally published by WRAL Techwire

DURHAM – Codetta Bio, a developer of biomarker measurement tools, has named a new chief executive officer.

Jacques Corriveau will lead Codetta’s next phase of commercial growth as the team advances the development of its disruptive multi-omic solution and brings its technology to market, the company says.

“Corriveau joins Codetta with more than 25 years of commercial and operational leadership in life science tools, biopharma, and diagnostics, and has demonstrated success in developing and growing early-stage companies,” Codetta says.

“Most recently, Corriveau served as President and CEO at Ultivue, Inc. for three years, where he led organizational growth in commercial operations and manufacturing capacity. Prior to that, he worked for AstraZeneca’s Definiens Inc. as Vice President and General Manager for North America. Corriveau also spent 10 years in various commercial roles at NanoString Technologies, where he created, developed, and executed go-to-market strategies.”

Former CEO Dr. Anthony Lemmo is now  chief technology officer.

To learn more about Codetta Bio, see http://www.codettabio.com.

The post Durham-based Codetta Bio names new CEO first appeared on WRAL TechWire.


Life Sciences

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Markets

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending